Abstract
Neuroendocrine carcinoma of the prostate (NEPC) is a rare entity. We aimed at providing contemporary data on incidence and survival figures of de-novo NEPC. Within the Surveillance, Epidemiology, and End Results (SEER) database, we identified 309 individuals with de-novo NEPC diagnosed between 2004 and 2013. We evaluated age-adjusted incidence rates over the study. Kaplan-Meier analyses assessed overall survival (OS) after stratification according to histologic subtype, metastatic status, and treatment. Cox regression analyses tested the predictors of overall mortality, after adjusting for confounders. A total of 309 cases of NEPC were identified from 510,913 cases of prostate cancer. Metastatic disease was identified in 198 (64.1%) cases. The most common histologic subtype (n = 186; 60.2%) was small-cell carcinoma (SCC). The age-adjusted incidence of NEPC significantly increased over the study span. However, this increase only affected SCC (from 0.13/1,000,000 person-years in 2004 to 0.30/1,000,000 person-years in 2013; P = .001). Median survival for NEPC was 10 months. After stratification by metastatic status, no difference was observed according to SCC versus non-SCC. Treatment with radical prostatectomy improved OS only am...Continue Reading
Citations
Jul 4, 2018·DNA and Cell Biology·Chao LuYong Xu
Jul 18, 2018·The Journal of Pathology·Edmund Cp ChedgyAlexander W Wyatt
Aug 30, 2018·The Prostate·Yinan LiXuesen Dong
Nov 26, 2019·American Journal of Clinical Oncology·Salman SyedZimu Gong
Feb 5, 2019·Oncotarget·Leonidas ApostolidisCarsten Grüllich
Jun 2, 2020·American Society of Clinical Oncology Educational Book·Benedito A CarneiroRahul Aggarwal
Jun 10, 2020·Cells·Xinpei CiYuzhuo Wang
Oct 25, 2017·Der Urologe. Ausg. A·S TritschlerM Hentrich
Aug 16, 2019·Pathology Oncology Research : POR·Noémi KránitzTamás Kullmann
Sep 14, 2019·World Journal of Nuclear Medicine·Matthew Q SchmidtBennett B Chin
Jun 28, 2018·Der Pathologe·S TritschlerM Hentrich
Aug 4, 2019·The Prostate·Jun WangDing-Wei Ye
Dec 14, 2018·Frontiers in Oncology·Charalampos PapagorasPanagiotis Skendros
Dec 20, 2018·Medicinal Research Reviews·N G R Dayan ElshanMichael E Jung
Feb 26, 2021·JAMA Oncology·Johannes StelwagenAnnemiek M E Walenkamp
Aug 4, 2020·Asian Journal of Urology·Ramesh Narayanan
Jul 23, 2021·Nature Reviews. Urology·Yong WangYuzhuo Wang
Aug 6, 2021·Oncogene·Su H ParkJindan Yu